AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33774558 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered exposure therapy
Number of subjects: 69
Study 33774558 — intervention group
Group type: COMPARATOR
Intervention: Internet-delivered cognitive behavioral therapy (iCBT)
Number of subjects: 69
Study 35218019 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature treatment (TTM) at 33°C for 24 or 48 hours
Number of subjects: 310
Study 32039840 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise training
Number of subjects: 101
Study 34988932 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroMuscular Taping (NMT) applied over 8 days following back-school therapy (BST)
Number of subjects: 0
Study 34988932 — intervention group
Group type: COMPARATOR
Intervention: Back-school therapy (BST) alone
Number of subjects: 0
Study 34472906 — intervention group
Group type: EXPERIMENTAL
Intervention: Socially inactive lifestyle
Number of subjects: 589
Study 34472906 — intervention group
Group type: EXPERIMENTAL
Intervention: Slightly unhealthy lifestyle
Number of subjects: 589
Study 34472906 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly physically active lifestyle
Number of subjects: 589
Study 34472906 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-promoting lifestyle
Number of subjects: 589
Study 34507361 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonyautoxin 2/3 (GTX 2/3) 40 ?g in 30 mL sodium chloride 0.9%
Number of subjects: 48
Study 34507361 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine (300 mg), ketorolac (60 mg), and epinephrine (1 mg) in 150 mL sodium chloride 0.9%
Number of subjects: 48
Study 34507361 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonyautoxin 2/3 (GTX 2/3)
Number of subjects: 48
Study 34507361 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine, ketorolac, and epinephrine
Number of subjects: 48
Study 34507361 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 34329947 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 151
Study 34329947 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 151
Study 34329947 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 151
Study 34263416 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + Er,Cr:YSGG laser
Number of subjects: 26
Study 34263416 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + diode laser
Number of subjects: 26
Study 34263416 — intervention group
Group type: COMPARATOR
Intervention: SRP-only
Number of subjects: 26
Study 34213641 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 233
Study 34213641 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on multivariable model including age, pre-operative hemoglobin count, and pre-operative albumin count
Number of subjects: 233
Study 32199540 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery Support Navigators (RSN)
Number of subjects: 4236
Study 32199540 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 4236
Study 35606826 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS applied to the left dorsolateral prefrontal cortex
Number of subjects: 0
Study 35606826 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0
Study 34615782 — intervention group
Group type: EXPERIMENTAL
Intervention: Avalon Avohex
Number of subjects: 52
Study 34615782 — intervention group
Group type: EXPERIMENTAL
Intervention: Listerine Miswak
Number of subjects: 52
Study 34615782 — intervention group
Group type: EXPERIMENTAL
Intervention: Optima Aloe Dent Mouthrinse
Number of subjects: 52
Study 34615782 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mouthrinse)
Number of subjects: 52
Study 32369989 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with extra virgin olive oil and nuts
Number of subjects: 67
Study 32369989 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric Mediterranean diet and intensive lifestyle program
Number of subjects: 67
Study 35968286 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Hz EA group
Number of subjects: 160
Study 35968286 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 Hz EA group
Number of subjects: 160
Study 35968286 — intervention group
Group type: EXPERIMENTAL
Intervention: 2/100 Hz EA group
Number of subjects: 160
Study 35968286 — intervention group
Group type: COMPARATOR
Intervention: Control group (Mecobalamin tablets)
Number of subjects: 160
Study 32376754 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemia-free liver transplantation (IFLT)
Number of subjects: 68
Study 32376754 — intervention group
Group type: COMPARATOR
Intervention: Conventional liver transplantation (CLT)
Number of subjects: 68
Study 35461026 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol
Number of subjects: 210
Study 35461026 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexketoprofen
Number of subjects: 210
Study 35461026 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ibuprofen
Number of subjects: 210
Study 34496751 — intervention group
Group type: EXPERIMENTAL
Intervention: Education based on Acceptance and Commitment Therapy (ACT)
Number of subjects: 6
Study 34496751 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 6
Study 32747146 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthognathic surgery
Number of subjects: 267
Study 32747146 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical controls
Number of subjects: 267
Study 35233984 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin (Z), 3.6 mg, n = 8
Number of subjects: 16
Study 33176437 — intervention group
Group type: EXPERIMENTAL
Intervention: Omecamtiv Mecarbil (OM) 25 mg BID
Number of subjects: 448
Study 33176437 — intervention group
Group type: EXPERIMENTAL
Intervention: Omecamtiv Mecarbil (OM) pharmacokinetically guided dose titration (OM-PK)
Number of subjects: 448
Study 33176437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 448
Study 33307907 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) consisting of 4 cycles of 5-min ischemia at 200 mmHg followed by 5-min reperfusion.
Number of subjects: 58
Study 33307907 — intervention group
Group type: COMPARATOR
Intervention: Sham-RIPC (control group).
Number of subjects: 58
Study 33307907 — intervention group
Group type: COMPARATOR
Intervention: Remote ischemic preconditioning (RIPC) and Sham-RIPC (control group).
Number of subjects: 58
Study 34662449 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhosis regression observed in 16% (176/1,135) between baseline and week 48 (W48)
Number of subjects: 1135
Study 34662449 — intervention group
Group type: COMPARATOR
Intervention: Nonregression of cirrhosis
Number of subjects: 1135
Study 34606293 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hygiene system (test group) involving a novel smart‐connected Oral‐B® iO oscillating‐rotating electric toothbrush, 0.454 percent stabilized stannous fluoride dentifrice, 0.07 percent cetylpyridinium chloride rinse, and floss
Number of subjects: 0
Study 34606293 — intervention group
Group type: COMPARATOR
Intervention: Control regimen involving a manual toothbrush and 0.243 percent sodium fluoride dentifrice
Number of subjects: 0
Study 32806525 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face exercise performed by an instructor (Group L)
Number of subjects: 117
Study 32806525 — intervention group
Group type: COMPARATOR
Intervention: Exercise using machines (Group P)
Number of subjects: 117
Study 34931313 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based CBT
Number of subjects: 80
Study 34931313 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 35200634 — intervention group
Group type: EXPERIMENTAL
Intervention: Dunaliella salina extract
Number of subjects: 0
Study 35200634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34246458 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 0
Study 34246458 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radiotherapy
Number of subjects: 0
Study 71031583 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis
Number of subjects: 607
Study 71031583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 607
Study 71031583 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Escherichia coli infections
Number of subjects: 607
Study 71031583 — intervention group
Group type: EXPERIMENTAL
Intervention: Escherichia coli infections
Number of subjects: 607
Study 71031583 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel and bladder dysfunction (BBD) assessment
Number of subjects: 607
Study 35373021 — intervention group
Group type: EXPERIMENTAL
Intervention: OkKidney app
Number of subjects: 80
Study 35373021 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (multidisciplinary renal team)
Number of subjects: 80
Study 32206812 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative early childhood intervention (ECI) services based on the International Classification of Functioning, Disability and Health framework and family‐centered approaches.
Number of subjects: 24
Study 32206812 — intervention group
Group type: COMPARATOR
Intervention: Regular home visits by local social workers (Control).
Number of subjects: 24
Study 33715648 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina supplementation
Number of subjects: 40
Study 33715648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 34282647 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-minute dilute povidone-iodine soak and scrub followed by standard 2-step skin preparation (alcohol scrub and chlorhexidine/alcohol paint)
Number of subjects: 242
Study 34282647 — intervention group
Group type: COMPARATOR
Intervention: Standard 2-step skin antiseptic preparation (alcohol scrub followed by chlorhexidine/alcohol paint)
Number of subjects: 242
Study 32985369 — intervention group
Group type: EXPERIMENTAL
Intervention: IV administration of 15 mg/kg TXA
Number of subjects: 174
Study 32985369 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TXA)
Number of subjects: 174
Study 35044035 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral cystolithotripsy (TUCL)
Number of subjects: 100
Study 35044035 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous cystolithotripsy (PCCL)
Number of subjects: 100
Study 33386426 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip arthroscopic osteochondroplasty
Number of subjects: 108
Study 35060544 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM)
Number of subjects: 25
Study 35060544 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study 34000245 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with concurrent temozolomide (75 mg/m2 per day)
Number of subjects: 751
Study 34000245 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 751
Study 34000245 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with adjuvant temozolomide (12 4-week cycles of 150-200 mg/m2 on days 1-5)
Number of subjects: 751
Study 34000245 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy without adjuvant temozolomide
Number of subjects: 751
Study 34475187 — intervention group
Group type: EXPERIMENTAL
Intervention: Acquire 22G TBNB needles
Number of subjects: 158
Study 34475187 — intervention group
Group type: COMPARATOR
Intervention: Standard 22G TBNA needles
Number of subjects: 158
Study 32208125 — intervention group
Group type: EXPERIMENTAL
Intervention: 100mg melatonin
Number of subjects: 30
Study 32208125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 33567888 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured yoga program for 12 weeks
Number of subjects: 113
Study 33567888 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 113
Study 32348280 — intervention group
Group type: COMPARATOR
Intervention: Control (pedometer only)
Number of subjects: 30
Study 32348280 — intervention group
Group type: EXPERIMENTAL
Intervention: App (pedometer synced to personal smartphone)
Number of subjects: 30
Study 32348280 — intervention group
Group type: EXPERIMENTAL
Intervention: App-coach (pedometer synced to personal smartphone + health coach)
Number of subjects: 30
Study 32348280 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study 36085679 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG neurofeedback (NFB) training for 12 weeks (24 sessions) targeting frontal gamma activity.
Number of subjects: 31
Study 36085679 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG neurofeedback (NFB) training using a brain-computer interface (BCI) delivering F3-F4 gamma coherence NFB.
Number of subjects: 31
Study 36085679 — intervention group
Group type: COMPARATOR
Intervention: Placebo neurofeedback (NFB) training.
Number of subjects: 31
Study 34547013 — intervention group
Group type: EXPERIMENTAL
Intervention: Myhixel I© device with Sphincter Control Training (SCT) program for 8 weeks
Number of subjects: 40
Study 34547013 — intervention group
Group type: COMPARATOR
Intervention: No device with Sphincter Control Training (SCT) program for 8 weeks
Number of subjects: 40
Study 36274214 — intervention group
Group type: EXPERIMENTAL
Intervention: etoposide-platinum-atezolizumab
Number of subjects: 41
Study 35584872 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide for 24 weeks
Number of subjects: 172
Study 35584872 — intervention group
Group type: COMPARATOR
Intervention: DPP-4 inhibitor
Number of subjects: 172
Study 33245161 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassion training
Number of subjects: 57
Study 33245161 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 57
Study 33245161 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 57
Study 33060078 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand-alone VR (6-week internet-based intervention with weekly online sessions and daily exercises)
Number of subjects: 322
Study 33060078 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended VR (stand-alone VR supplemented with face-to-face physiotherapy support)
Number of subjects: 322
Study 33060078 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 322
Study 35383253 — intervention group
Group type: EXPERIMENTAL
Intervention: Solacea 19H dialyzer with 1/4th of the regular anticoagulation dose
Number of subjects: 10
Study 35383253 — intervention group
Group type: COMPARATOR
Intervention: FX800 CorDiax dialyzer
Number of subjects: 10
Study 33148184 — intervention group
Group type: EXPERIMENTAL
Intervention: Community recruitment strategies
Number of subjects: 234
Study 34271175 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD-Clinical Decision Support (CKD-CDS) intervention
Number of subjects: 7000
Study 34271175 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 7000
Study 33016688 — intervention group
Group type: COMPARATOR
Intervention: Smoking individuals (both men and women)
Number of subjects: 2413
Study 33016688 — intervention group
Group type: COMPARATOR
Intervention: Male smoking population
Number of subjects: 2413
Study 33016688 — intervention group
Group type: EXPERIMENTAL
Intervention: Income level
Number of subjects: 2413
Study 33016688 — intervention group
Group type: EXPERIMENTAL
Intervention: Single women and men
Number of subjects: 2413
Study 33016688 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals from small towns (less than 50,000 inhabitants)
Number of subjects: 2413
Study 34030944 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer-stay group (n = 150)
Number of subjects: 230
Study 34030944 — intervention group
Group type: COMPARATOR
Intervention: Shorter-stay group (n = 80)
Number of subjects: 230
Study 34471722 — intervention group
Group type: EXPERIMENTAL
Intervention: d-alpha tocopheryl acetate products
Number of subjects: 15
Study 34471722 — intervention group
Group type: COMPARATOR
Intervention: octyl palmitate (positive control)
Number of subjects: 15
Study 34471722 — intervention group
Group type: COMPARATOR
Intervention: negative control (no test material)
Number of subjects: 15
Study 34213007 — intervention group
Group type: EXPERIMENTAL
Intervention: Anderson-Rubin test
Number of subjects: 0
Study 34213007 — intervention group
Group type: EXPERIMENTAL
Intervention: Kleibergen test
Number of subjects: 0
Study 34213007 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional likelihood ratio test
Number of subjects: 0
Study 34184784 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleep
Number of subjects: 398137
Study 34184784 — intervention group
Group type: EXPERIMENTAL
Intervention: Long sleep
Number of subjects: 398137
Study 34184784 — intervention group
Group type: EXPERIMENTAL
Intervention: Sometimes insomnia
Number of subjects: 398137
Study 34184784 — intervention group
Group type: EXPERIMENTAL
Intervention: Usually insomnia
Number of subjects: 398137
Study 34184784 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite eveningness
Number of subjects: 398137
Study 34184784 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite morningness
Number of subjects: 398137
Study 34184784 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleep (men)
Number of subjects: 398137
Study 34184784 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleep (premenopausal women)
Number of subjects: 398137
Study 34184784 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleep, eveningness, and daytime sleepiness (postmenopausal women)
Number of subjects: 398137
Study 34184784 — intervention group
Group type: COMPARATOR
Intervention: Mendelian randomization analyses
Number of subjects: 398137
Study 34058910 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngoplasty or voice therapy
Number of subjects: 439
Study 34058910 — intervention group
Group type: COMPARATOR
Intervention: Voice therapy alone
Number of subjects: 439
Study 34058910 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 439
Study 34639285 — intervention group
Group type: EXPERIMENTAL
Intervention: In-service training program
Number of subjects: 81
Study 34639285 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 81
Study 34010180 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI with everolimus‐eluting stents
Number of subjects: 1895
Study 34010180 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1895
Study 34010180 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing WBCc tertiles (mean 5.6, 7.5, and 10.1 × 10^9/L)
Number of subjects: 1895
Study 34010180 — intervention group
Group type: EXPERIMENTAL
Intervention: WBCc as a continuous variable
Number of subjects: 1895
Study 34010180 — intervention group
Group type: EXPERIMENTAL
Intervention: WBCc tertiles
Number of subjects: 1895
Study 32526017 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS + exercise therapies
Number of subjects: 60
Study 32526017 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS + exercise therapies
Number of subjects: 60
Study 36457045 — intervention group
Group type: EXPERIMENTAL
Intervention: digital cognitive-behavioral therapy for insomnia (dCBT-I)
Number of subjects: 0
Study 36457045 — intervention group
Group type: EXPERIMENTAL
Intervention: clinician-led cognitive-behavioral therapy for insomnia (CBT-I)
Number of subjects: 0
Study 36457045 — intervention group
Group type: COMPARATOR
Intervention: sleep education control
Number of subjects: 0
Study 33259846 — intervention group
Group type: EXPERIMENTAL
Intervention: ILMN_1765146 tagging IFNAR2
Number of subjects: 0
Study 33259846 — intervention group
Group type: EXPERIMENTAL
Intervention: ILMN_1791057 tagging IFNAR2
Number of subjects: 0
Study 36261277 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week interruption in methotrexate treatment
Number of subjects: 0
Study 36261277 — intervention group
Group type: COMPARATOR
Intervention: Continued methotrexate treatment
Number of subjects: 0
Study 34554692 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium 200 µg
Number of subjects: 80
Study 34554692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 35452086 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine maintenance therapy using lower dosage and higher frequency
Number of subjects: 0
Study 35452086 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study 33303575 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD1 immunotherapy
Number of subjects: 0
Study 33303575 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-molecule inhibitor targeting HO-1
Number of subjects: 0
Study 33303575 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ox-LDL
Number of subjects: 0
Study 33303575 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HMOX1 (HO-1) expression
Number of subjects: 0
Study 34877769 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 474
Study 34877769 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine-naloxone (BUP-NX)
Number of subjects: 474
Study 33009852 — intervention group
Group type: EXPERIMENTAL
Intervention: Take 5 Minutes treatment (5 to 10 minutes of dedicated communication with parents)
Number of subjects: 191
Study 33009852 — intervention group
Group type: EXPERIMENTAL
Intervention: Take 5 Minutes treatment
Number of subjects: 191
Study 33009852 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 191
Study 34719633 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete denture relined with silicone-based resilient denture liner (RD)
Number of subjects: 0
Study 34719633 — intervention group
Group type: COMPARATOR
Intervention: Conventional complete denture (CD)
Number of subjects: 0
Study 34246226 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly fremanezumab (225 mg)
Number of subjects: 807
Study 34246226 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly fremanezumab (225 mg)
Number of subjects: 807
Study 34246226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 807
Study 34246226 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 807